Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates

Stock Information for Tonix Pharmaceuticals Holding Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Tonix Pharmaceuticals Holding Corp.

Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates
Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial
Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai(TM)
Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic(TM) Clinical Trial in Japan for LP-300
Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors
Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial
Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy
IBN Initiates Coverage of Lantern Pharma Inc.

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.